Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

MAVMET trial: maraviroc and/or metformin for metabolic dysfunction-associated fatty liver disease(MAFLD) in adults with suppressed HIV.

Mccabe L. et al, (2024), AIDS (London, England)

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

Liew F. et al, (2024), Nature Immunology, 25, 607 - 621

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).

Paton NI. et al, (2024), EClinicalMedicine, 69

Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis.

White P. et al, (2023), Journal of neurology, neurosurgery, and psychiatry

Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza

Vanderven HA. et al, (2023), JCI Insight

Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers.

McCann N. et al, (2023), BMJ Open, 13

Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.

Siggins MK. et al, (2023), Immunology, 168, 473 - 492

The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.

Goldswain H. et al, (2023), Genome biology, 24

Malaria patient spectrum representation in therapeutic clinical trials of uncomplicated malaria: a scoping review of the literature.

Arena L. et al, (2023), Malaria journal, 22

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Liew F. et al, (2023), eBioMedicine, 87, 104402 - 104402

Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study.

Vink E. et al, (2022), Open forum infectious diseases, 9

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

Mentzer AJ. et al, (2022), Nature Medicine

Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19

Kotanidis CP. et al, (2022), The Lancet Digital Health, 4, e705 - e716

Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number

Keeling MJ. et al, (2022), Statistical Methods in Medical Research, 31, 1716 - 1737

Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19

Norris T. et al, (2022), Heart, 108, 1200 - 1208

Mucosal-Associated Invariant T cells exhibit distinct functional signatures associated with protection against typhoid fever

Salerno-Gonçalves R. et al, (2022), Cellular Immunology, 378

Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study.

Millar JE. et al, (2022), Scientific reports, 12

Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.

Närhi F. et al, (2022), The Lancet. Digital health, 4, e220 - e234

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Fisher BA. et al, (2022), The Lancet Respiratory Medicine, 10, 255 - 266

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?